The combination of azacitidine with a specific BCL-XL inhibitor seems to be particularly attractive since azacitidine does not only interfere with BCL-2 family homeostasis but also induces the differentiation of JMML cells to mature granulocytes. Here, BCL2L1 is linked to juvenile myelomonocytic leukemia.